This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davis, M. Articles by Campbell, I. G. Search for Related Content PubMed PubMed Citation Articles by Davis, M. Articles by Campbell, I. G.

Refinement of Two Chromosome 11q Regions of Loss of Heterozygosity in Ovarian Cancer¹

Obstetrics and Gynecology, University of Southampton, Princess Anne Hospital, Coxford Road, Southampton SO165YA, United Kingdom [M. D., I. G. C.]; Department of Histopathology, Southampton General Hospital, Tremona Road, Southampton, 5016 6YD United Kingdom [A. H.]; and Division of Medical Genetics, Department of Medicine, Montreal General Hospital, Montreal, Quebec, H3G 1A4, Canada [W. D. F.]

Loss of heterozygosity on chromosome 11q23.3-qter is a frequent event in ovarian carcinoma, implying the existence of an important ovarian tumor suppressor gene(s) within the region. To refine a minimum region(s) of loss, 67 ovarian tumors were analyzed for loss of heterozygosity with eight microsatellite markers spanning 11q23.3-qter. Forty tumors (61%) demonstrated allelic losses. Twenty-seven of these had allelic losses on only part of 11q23.3, which enabled the identification of two distinct regions likely to harbor ovarian tumor suppressor genes. The proximal region, flanked by markers D11S925 and D11S1336, is less than two megabases while the second more distal region, flanked by markers D11S912 and D11S439, is approximately eight megabases. The refinement of these candidate tumor suppressor gene loci will facilitate future loss of heterozygosity studies and enable the isolation of candidate genes from these regions.

¹ Supported by Sarum Road Private Hospital, The Heller Trust, and The Spiro Trust (all to M. D.). This work was also partly supported by Wellbeing and the Wessex Medical Trust.

² To whom requests for reprints should be addressed.

Received 11/24/95. Accepted 12/28/95.

This article has been cited by other articles:

				J. J. Peluso, X. Liu, M. M. Saunders, K. P. Claffey, and K. Phoenix Regulation of Ovarian Cancer Cell Viability and Sensitivity to Cisplatin by Progesterone Receptor Membrane Component-1 J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1592 - 1599. [Abstract] [Full Text] [PDF]

				J.-S. Jin, A. Chen, D.-S. Hsieh, C.-W. Yao, M.-F. Cheng, and Y.-F. Lin Expression of Serine Protease Matriptase in Renal Cell Carcinoma: Correlation of Tissue Microarray Immunohistochemical Expression Analysis Results with Clinicopathological Parameters International Journal of Surgical Pathology, January 1, 2006; 14(1): 65 - 72. [Abstract] [PDF]

				Q. Feng, P. Li, C. Salamanca, D. Huntsman, P. C.K. Leung, and N. Auersperg Caspase-1{alpha} Is Down-regulated in Human Ovarian Cancer Cells and the Overexpression of Caspase-1{alpha} Induces Apoptosis Cancer Res., October 1, 2005; 65(19): 8591 - 8596. [Abstract] [Full Text] [PDF]

				F. Modugno Ovarian Cancer and Polymorphisms in the Androgen and Progesterone Receptor Genes: A HuGE Review Am. J. Epidemiol., February 15, 2004; 159(4): 319 - 335. [Abstract] [Full Text] [PDF]

				E. S. Martin, R. Cesari, F. Pentimalli, K. Yoder, R. Fishel, A. L. Himelstein, S. E. Martin, A. K. Godwin, M. Negrini, and C. M. Croce The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene PNAS, September 30, 2003; 100(20): 11517 - 11522. [Abstract] [Full Text] [PDF]

				M. D. Oberst, M. D. Johnson, R. B. Dickson, C.-Y. Lin, B. Singh, M. Stewart, A. Williams, A. al-Nafussi, J. F. Smyth, H. Gabra, et al. Expression of the Serine Protease Matriptase and Its Inhibitor HAI-1 in Epithelial Ovarian Cancer: Correlation with Clinical Outcome and Tumor Clinicopathological Parameters Clin. Cancer Res., April 1, 2002; 8(4): 1101 - 1107. [Abstract] [Full Text] [PDF]

				G. C. Sellar, L. Li, K. P. Watt, B. D. Nelkin, G. J. Rabiasz, E. A. Stronach, E. P. Miller, D. J. Porteous, J. F. Smyth, and H. Gabra BARX2 Induces Cadherin 6 Expression and Is a Functional Suppressor of Ovarian Cancer Progression Cancer Res., October 1, 2001; 61(19): 6977 - 6981. [Abstract] [Full Text] [PDF]

				R. L. Auer, C. Jones, R. A. Mullenbach, D. Syndercombe-Court, D. W. Milligan, C. D. Fegan, and F. E. Cotter Role for CCG-trinucleotide repeats in the pathogenesis of chronic lymphocytic leukemia Blood, January 15, 2001; 97(2): 509 - 515. [Abstract] [Full Text] [PDF]

				H. A. Pulido, M. J. Fakruddin, A. Chatterjee, E. D. Esplin, N. Beleno, G. Martinez, H. Posso, G. A. Evans, and V. V. V. S. Murty Identification of a 6-cM Minimal Deletion at 11q23.1-23.2 and Exclusion of PPP2R1B Gene as a Deletion Target in Cervical Cancer Cancer Res., December 1, 2000; 60(23): 6677 - 6682. [Abstract] [Full Text]

				S. Knuutila, Y. Aalto, K. Autio, A.-M. Bjorkqvist, W.'e. El-Rifai, S. Hemmer, T. Huhta, E. Kettunen, S. Kiuru-Kuhlefelt, M. L. Larramendy, et al. DNA Copy Number Losses in Human Neoplasms Am. J. Pathol., September 1, 1999; 155(3): 683 - 694. [Abstract] [Full Text] [PDF]

				K. C. Connolly, H. Gabra, C. J. Millwater, K. J. Taylor, G. J. Rabiasz, J. E. V. Watson, J. F. Smyth, A. H. Wyllie, and D. I. Jodrell Identification of a Region of Frequent Loss of Heterozygosity at 11q24 in Colorectal Cancer Cancer Res., June 1, 1999; 59(12): 2806 - 2809. [Abstract] [Full Text] [PDF]

				K.-M. Lau, S. C. Mok, and S.-M. Ho Expression of human estrogen receptor-alpha and -beta , progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells PNAS, May 11, 1999; 96(10): 5722 - 5727. [Abstract] [Full Text] [PDF]